Apotex Warning Letter Demands List Of Products That Might Enter U.S.
This article was originally published in PharmAsia News
Executive Summary
FDA already has Bangalore, India plant on an import alert, but the agency may be preparing to go after API from the facility as well after finding persistent use of questionable testing data.
You may also be interested in...
Confronting Illusions of Quality in Indian Generics Manufacturing
A sharp increase in data integrity findings has raised questions about the quality of pharmaceutical manufacturing in India. What’s happening and why, who’s responsible, and how can drug makers and the regulatory agencies that watch over them put a stop to it?
Drug Shortages Mostly FDA’s Fault, House Oversight Committee Concludes
Report says aggressive enforcement in recent years has forced capacity offline, which led to shortages.
Harmonizing COVID Vaccine Schedule Good Idea, But US FDA Should Remain Flexible, Advisors Say
Vaccines and Related Biological Products Advisory Committee also said that more data is needed to determine the groups that potentially could receive more than one periodic vaccine booster.